Literature DB >> 3670047

Specificity of proto-oncogene amplification in human malignant diseases.

H Masuda1, H Battifora, J Yokota, S Meltzer, M J Cline.   

Abstract

DNAs from 253 fresh human tumors of 38 different types were hybridized with 17 different oncogene probes. The analysis demonstrated unique associations between amplification of specific oncogenes and specific types of tumors. In a large number of cases it was determined that amplified oncogenes occurred in 10 to 20% of tumors with the following specific associations: c-myc in adenocarcinomas, squamous carcinomas and sarcomas but not hematologic malignancies; c-erbB2 in adenocarcinomas, particularly breast cancers; c-erbB1 in squamous carcinomas; N-myc in neuroblastomas. A small number of cases suggested other specific associations: amplified c-myb in breast cancers; amplified c-ras-Ha and c-ras-Ki in ovarian carcinomas. In addition, there was a correlation between amplification of c-myc and the clinical stage of adenocarcinomas, and amplification of c-erbB2 and the clinical stage and lymph node involvement of breast cancers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3670047

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  9 in total

1.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  DNA amplification is rare in normal human cells.

Authors:  J A Wright; H S Smith; F M Watt; M C Hancock; D L Hudson; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; S H Advani; S Benchimol; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

Authors:  P A van Dam; I B Vergote; D G Lowe; J V Watson; P van Damme; J C van der Auwera; J H Shepherd
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

5.  Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.

Authors:  D L Persons; L C Hartmann; J F Herath; T J Borell; W A Cliby; G L Keeney; R B Jenkins
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

6.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

7.  Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659----Glu659).

Authors:  Y Suda; S Aizawa; Y Furuta; T Yagi; Y Ikawa; K Saitoh; Y Yamada; K Toyoshima; T Yamamoto
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

8.  Amplification of the MYC Gene in Osteosarcoma Secondary to Paget's Disease of Bone.

Authors:  T Ueda; J H Healey; A G Huvos; M Ladanyi
Journal:  Sarcoma       Date:  1997

9.  Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.

Authors:  M Fujita; T Enomoto; M Inoue; O Tanizawa; M Ozaki; J M Rice; T Nomura
Journal:  Jpn J Cancer Res       Date:  1994-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.